199 related articles for article (PubMed ID: 21698529)
1. [Advanced therapy medicinal products : Scientific, medical, economic, and ethical aspects].
Seitz R; Schneider CK; Hengel H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):789-90. PubMed ID: 21698529
[No Abstract] [Full Text] [Related]
2. [A comprehensive assessment of ATMP. Difficulties and approaches].
Thanner M; Nagel E
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):843-8. PubMed ID: 21698538
[TBL] [Abstract][Full Text] [Related]
3. [Regulatory framework of innovative therapies : From bench to bedside].
Walter C; Rohde B; Wicke DC; Pohler C; Lührmann A; von der Leyen H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):803-10. PubMed ID: 21698532
[TBL] [Abstract][Full Text] [Related]
4. [Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products].
Reiss M; Büttel IC; Schneider CK
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):822-30. PubMed ID: 21698535
[TBL] [Abstract][Full Text] [Related]
5. [Regulation (EC) No. 1394/2007 on advanced therapy medicinal products : Incorporation into national law].
Dwenger A; Strassburger J; Schwerdtfeger W
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):14-9. PubMed ID: 20033662
[TBL] [Abstract][Full Text] [Related]
6. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation].
Buljovčić Z
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536
[TBL] [Abstract][Full Text] [Related]
7. [Reimbursement of new medical therapy].
Ehlers AP; Wenke A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):849-55. PubMed ID: 21698539
[TBL] [Abstract][Full Text] [Related]
8. Japan responds: stem-cell therapy justified.
Miyamoto S
Nature; 2019 May; 569(7754):40. PubMed ID: 31040418
[No Abstract] [Full Text] [Related]
9. [Classification of cell-based medicinal products and legal implications: An overview and an update].
Scherer J; Flory E
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1201-6. PubMed ID: 26369760
[TBL] [Abstract][Full Text] [Related]
10. [What is the fair price of innovative therapy?].
Fischer A; Dewatripont M; Goldman M
Med Sci (Paris); 2020 Apr; 36(4):389-393. PubMed ID: 32356716
[TBL] [Abstract][Full Text] [Related]
11. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products.
Lucas-Samuel S; Ferry N; Trouvin JH
Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive resource on EU regulatory information for investigators in gene therapy clinical research and advanced therapy medicinal products.
Cohen-Haguenauer O
Hum Gene Ther; 2013 Jan; 24(1):12-8. PubMed ID: 23339285
[No Abstract] [Full Text] [Related]
13. [Regulatory requirements regarding cell-based medicinal products for human and veterinary use - a comparison].
Kuhlmann-Gottke J; Duchow K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1299-305. PubMed ID: 26369765
[TBL] [Abstract][Full Text] [Related]
14. Legal and ethical status of stem cells as medicinal products.
Tsang L
Adv Drug Deliv Rev; 2005 Dec; 57(13):1970-80. PubMed ID: 16297498
[TBL] [Abstract][Full Text] [Related]
15. Texas signals support for unproven stem cell therapies.
Servick K
Science; 2017 Jun; 356(6344):1219. PubMed ID: 28642387
[No Abstract] [Full Text] [Related]
16. [Clinical trials with advanced therapy medicinal products].
Schüssler-Lenz M; Schneider CK
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):68-74. PubMed ID: 20011994
[TBL] [Abstract][Full Text] [Related]
17. [Important aspects of virus safety of advanced therapy medicinal products].
Blümel J; Stühler A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):38-44. PubMed ID: 19937308
[TBL] [Abstract][Full Text] [Related]
18. Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany.
Renner M; Anliker B; Sanzenbacher R; Schuele S
Adv Exp Med Biol; 2015; 871():87-101. PubMed ID: 26374214
[TBL] [Abstract][Full Text] [Related]
19. Neuroregenerative gene therapy: the implications for informed consent laws.
Sivarajah N
Health Law Can; 2005 Nov; 26(2):19-28. PubMed ID: 16736945
[No Abstract] [Full Text] [Related]
20. [From basic research to the clinic. Regulations for preclinical and clinical studies with stem cells].
Steinhoff G; Tiedemann G; Thalheimer M; Ho AD
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Sep; 51(9):973-9. PubMed ID: 18773175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
